HIV Persists: What Can We Do About It?

HIV Persists: What Can We Do About It?

The HIV epidemic endures within the global health sphere. As of 2022, approximately 39 million people live with HIV/AIDS worldwide; eliminating the viral threat remains challenging. Scientific and clinical efforts to eradicate HIV/AIDS have been ongoing for decades, yet we are still left without a vaccine or cure for the virus. But there is still much hope and promise in modern research. Major strides have been made in developing therapies for people living with HIV and preventing new infections within communities. The light at the end of the tunnel grows brighter as research and development ramp up. In this week’s episode, we invited the Chief of Pitt’s Division of Infectious Diseases, John Mellors, MD, as well as Associate Professor of Medicine, Bernard “Beej” Macatangay, MD, to discuss the current state of HIV research. Please join us as we consider the unusual characteristics of HIV and why they create difficulties in vaccine development. We also discuss approaches to treatment as prevention, the roles vaccines play in therapeutic HIV treatments, and developments in reaching undetectable status. Is there hope for an end to the epidemic?

Inoculation Imagination

Vaccine hesitancy, defined as reluctance or refusal to have oneself or one's children vaccinated against infectious diseases, is certainly not a modern novelty. In recent years, however, the idea has inspired the emergence of socio-political groups and organizations that make up what is now referred to as the “anti-vax” movement. Once a fringe outlier in the public health sphere, the anti-vax movement has slowly, but surely crept its way into mainstream politics. Although today’s anti-vaccine sentiments are largely politically-motivated, the growing opposition to vaccines has now begun to exhibit real world consequences. But how and when did it all begin? And what could lower vaccination rates in the US mean for the future of public health? This week, we investigate vaccine hesitancy with Drs. Karin Byers, MD, MS, Clinical Director for the Division of Infectious Diseases, and Sahil Angelo, MD, a current ID fellow at UPMC. Join us as we explore the history of vaccine opposition, consider how the COVID-19 pandemic influenced vaccine hesitancy, and examine the current state of the anti-vax movement.

A Vigilant Voyage

Join us for a trip around the world and back in this week’s episode of Microbe Matters! Globetrotting can be an exhilarating and fulfilling experience, but it can also present new potential health risks. We sit down with Carolyn Fernandes, MD, FIDSA, to discuss travel health services and the importance of preparedness when traveling abroad. In this episode, we identify various common pathogens, where they are in the world, and how to avoid disease when taking a trip. Dr. Fernandes also walks us through the pre-travel assessment process, as well as the numerous safety precautions one can follow to stay healthy. The threat of alien antigens may be unnerving to some, but don’t worry! Be prepared, not scared!

Breaking the Chain

Microbe Matters returns with an all new season of bugs, drugs, and more! As the world starts to ease its restrictions initiated by the COVID-19 pandemic, its inhabitants are left to wonder what will come next. This season, we explore the various roles vaccines play in infection prevention, travel health, socio-political movements, and therapeutic treatments. Tony kicks off season 2 by introducing Dr. Elise Martin, Medical Director of Infection Prevention and Hospital Epidemiology at the Veteran Affairs Pittsburgh Healthcare System, as well as Assistant  Professor of Medicine at the University of Pittsburgh. In this episode, we discuss how vaccines work, who should get them, and how they play a crucial part in preventing the spread of infections in health care and related environments.

STIs, Oh My!

This episode, we switch gears a little bit to talk about sex!  Tony sits down with Dr. Ken Ho, Associate Professor of Medicine at the University of Pittsburgh, and Dr. Linda Nabha, Assistant Professor of Medicine at Pitt as well. So far in our pilot season, we've discussed the threat that antibiotic resistance poses in and outside of hospitals, but did you know that there are some sexually transmitted infections that are beginning to develop drug-resistance as well?  This week we discuss the importance of routine sexual health screenings, preventative measures and treatments for STIs. We also list the various options for HIV pre-exposure prophylaxis (PrEP) and reasons why it might be right for you. Lastly, we attempt to demystify the stigmas surrounding STI infections and encourage inclusive public health messaging.